anti-CD33 CAR NK cell therapy (Miltenyi Biotec/University Hospital Berlin)

N/A

Report date: 2025/03/14 16:31:41

Base Information

Drug Nameanti-CD33 CAR NK cell therapy (Miltenyi Biotec/University Hospital Berlin)
Drug Alias NameCD33-CAR-NK cells (Miltenyi Biotec/University Hospital Berlin)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionMyeloid cell surface antigen CD33 modulators
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCharité – Universitätsmedizin Berlin
China Registration ClassN/A

Develop Information

Active CompaniesMiltenyi GmbHCharité – Universitätsmedizin Berlin
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A